This is a MapMyTimes opinion piece. It responds to the statewide compliance order on health supplements issued by Maharashtra's Food and Drug Administration (FDA) under Commissioner Tukaram Mundhe and reported on 20 November 2026, which requires gyms, fitness centres and pharmacies that sell protein powders and nutraceuticals to hold a food licence or registration from the Food Safety and Standards Authority of India (FSSAI). MapMyTimes reported the order the same day. Our view: the direction is right, but its credibility now depends on how fairly and openly it is enforced.
Why the order makes sense
Supplements are sold as food, not medicine, yet many buyers meet them at a gym counter or a chemist's shelf, places that carry an air of expert approval. According to a Press Trust of India report, the order makes clear that such sellers need a food licence or registration even if they already hold licences under other laws. That puts the point of sale, not just the factory, inside food-safety oversight.
The FDA did not act on theory. PTI reported that inspections on 13 November at 17 establishments across six divisions led to the seizure of stock worth about ₹1.39 crore. Officials said manufacturers were using Magnesium Acetyl Taurate and Nicotinamide Mononucleotide (NMN), two ingredients for which FSSAI had rejected product-approval applications. The regulator also cited concern over possible undeclared steroids and drug substances in sports-nutrition, weight-loss, sexual-wellness and herbal products.
The advertising rules are equally sensible. Under the order, as reported by PTI and the Free Press Journal, products cannot claim to treat, cure or prevent disease, cannot say they are recommended by doctors or nutritionists, and cannot use physicians' photographs. The rules extend to influencer posts and e-commerce listings, which is where much supplement marketing now happens. A buyer deserves to know that a tub of powder is a food product, not a prescription.
The strongest case against
There is a serious counter-argument, and it deserves a fair hearing. First, gyms and pharmacies are already regulated businesses, and a second licence adds paperwork and cost for small operators who are not making the products, only reselling them. Second, the reports say the order took effect immediately and set no separate deadline for gyms and pharmacies to apply, which leaves honest sellers unsure whether they are already in breach.
Third, the evidence is still incomplete. PTI reported that samples from the November raids have been sent to laboratories, and that further legal action will depend on the food analyst's report. Until those results are out, the seized stock is a case of suspected non-compliance, not proven harm.
Fourth, the FDA's own recent record invites caution. In August 2026, a Bombay High Court bench of Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad criticised the regulator for "undue haste" in two unrelated actions, and the FDA withdrew both orders, according to PTI. The bench told the regulator it was doing "a laudable and appreciative job, but now you are going overboard." Mundhe later told PTI that public health, not popularity, drives his department's work.
These concerns are real. But they argue for better enforcement, not for dropping the rules. FSSAI had already rejected approval for the two ingredients at the centre of the raids, and the Free Press Journal reported on 17 November that NMN is prohibited under an FSSAI direction dated 3 June 2026. The state order mainly makes clear who is responsible at the point of sale.
What would make it work
Four steps would strengthen the order without weakening it.
- A clear grace period. The FDA should publish a dated window for gyms and pharmacies to register, with simple guidance, before penalties apply to sellers who only resell sealed products.
- Published test results. When the laboratory reports on the 13 November samples arrive, the FDA should release the findings, product by product, so that the public can see what was actually wrong.
- Due process every time. Notices, hearings and reasoned orders should precede suspensions, as the High Court has asked. That protects both businesses and the regulator's authority.
- Focus on the source. The FDA has said it will prioritise risk-based inspections of the state's 1,100 supplement and nutraceutical licence holders, including 313 manufacturers. That is where the heaviest scrutiny belongs.
Maharashtra has taken a step that other states may watch closely. If it pairs firm rules with clear timelines and open evidence, it can show that consumer protection and fair treatment of business are not in conflict.




